We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.9B
1-Year Est. Return 169.69%
This Fund
S&P 500
This Quarter Est. Return
+26.15%
1 Year Est. Return
+169.69%
3 Year Est. Return
+507.65%
5 Year Est. Return
+746.04%
10 Year Est. Return
–
AUM
$2.9B
AUM Growth
+$433M
Cap. Flow
-$46.5M
Cap. Flow %
-1.6%
Top 10 Hldgs %
48.91%
Holding
114
New
21
Increased
25
Reduced
41
Closed
17

Top Buys

Rank Stock Value
1
PODD icon
Insulet
PODD
+$81.1M
2
INSP icon
Inspire Medical Systems
INSP
+$64.3M
3
RIGL icon
Rigel Pharmaceuticals
RIGL
+$56.6M
4
CELC icon
Celcuity
CELC
+$48.5M
5
PBLS
Parabilis Medicines Inc
PBLS
+$40.5M

Top Sells

Rank Stock Value
1
TWST icon
Twist Bioscience
TWST
+$73M
2
KRYS icon
Krystal Biotech
KRYS
+$63.9M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$48.4M
4
TGTX icon
TG Therapeutics
TGTX
+$45.1M
5
VCEL icon
Vericel Corp
VCEL
+$39.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JBIO
26
Jade Biosciences
JBIO
$1.27B
$34.5M 1.19%
1,550,690
+753,946
+95% +$15.7M
UNH icon
27
UnitedHealth
UNH
$356B
$33.3M 1.15%
+80,000
New +$29.7M
AVTX icon
28
Avalo Therapeutics
AVTX
$1.03B
$30.6M 1.05%
1,654,978
+1,213,000
+274% +$19.2M
URGN icon
29
UroGen Pharma
URGN
$2.16B
$30.5M 1.05%
829,810
+102,810
+14% +$2.79M
MBX
30
MBX Biosciences
MBX
$2.97B
$28.4M 0.98%
515,279
+336,382
+188% +$11.7M
PALI icon
31
Palisade Bio
PALI
$364M
$27.3M 0.94%
+13,063,687
New +$25.7M
PHVS icon
32
Pharvaris
PHVS
$2.47B
$25.3M 0.87%
730,907
+28,855
+4% +$873K
ORGO icon
33
Organogenesis Holdings
ORGO
$220M
$24.6M 0.85%
10,140,951
+55,000
+0.5% +$134K
SUPN icon
34
Supernus Pharmaceuticals
SUPN
$2.53B
$24.2M 0.83%
+520,000
New +$25M
PRCT icon
35
Procept Biorobotics
PRCT
$1.3B
$22.6M 0.78%
1,003,000
+843,000
+527% +$21.1M
TNGX icon
36
Tango Therapeutics
TNGX
$3.8B
$22.2M 0.76%
709,000
+259,000
+58% +$6.4M
IKT icon
37
Inhibikase Therapeutics
IKT
$349M
$22.1M 0.76%
10,875,000
– –
TRVI icon
38
Trevi Therapeutics
TRVI
$2.46B
$22M 0.76%
1,179,618
-440,382
-27% -$6.4M
BMRN icon
39
BioMarin Pharmaceuticals
BMRN
$12.9B
$21.5M 0.74%
375,572
-275,000
-42% -$15.1M
LIVN icon
40
LivaNova
LIVN
$4.51B
$21M 0.72%
254,957
-327,543
-56% -$23.2M
ARGX icon
41
argenx
ARGX
$64.6B
$18.5M 0.64%
19,955
+16,455
+470% +$13.6M
NVCT icon
42
Nuvectis Pharma
NVCT
$799M
$18.4M 0.63%
+1,000,000
New +$11.2M
CAPR icon
43
Capricor Therapeutics
CAPR
$547M
$18.3M 0.63%
+761,737
New +$23.1M
EWTX icon
44
Edgewise Therapeutics
EWTX
$4.68B
$18.3M 0.63%
450,889
-999,026
-69% -$34.4M
PRLD icon
45
Prelude Therapeutics
PRLD
$436M
$18M 0.62%
+3,378,378
New +$14.7M
XENE icon
46
Xenon Pharmaceuticals
XENE
$5.79B
$16.1M 0.56%
267,000
-25,000
-9% -$1.39M
CCCC icon
47
C4 Therapeutics
CCCC
$463M
$15.8M 0.54%
3,377,981
-425,961
-11% -$1.46M
KNSA icon
48
Kiniksa Pharmaceuticals
KNSA
$6.08B
$15.8M 0.54%
246,353
-275,000
-53% -$14.3M
KIDS icon
49
OrthoPediatrics
KIDS
$585M
$14M 0.48%
732,144
+116,697
+19% +$2.03M
AVLN
50
Avalyn Pharma
AVLN
$1.66B
$13.8M 0.48%
+419,000
New +$12.1M
1
2
3 4 5

Similar funds

GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
7WCP
71 West Capital Partners Boston, Massachusetts $2.89B AUM
ACM
Aquatic Capital Management Chicago, Illinois $2.91B AUM 27.09% 1-Year Est. Return
HWA
Heritage Wealth Advisors Richmond, Virginia $2.91B AUM 24.25% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.89B AUM 29.25% 1-Year Est. Return
WPW
Waldron Private Wealth Bridgeville, Pennsylvania $2.89B AUM 23.18% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return

Soleus Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Soleus Capital Management held 114 positions worth $2.9B, up 18% from $2.47B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Soleus Capital Management's Q2 2026 filing shows 21 new, 25 increased, 41 reduced and 17 closed positions. Its largest new stake was Parabilis Medicines Inc: 1,465,070 shares worth $40.1M. The largest sale was Twist Bioscience, an estimated $73M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Soleus Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 1,465,070 shares worth $40.1M.
  • Soleus Capital Management added most to Insulet in Q2 2026, an estimated $81.1M increase.
  • Soleus Capital Management's biggest Q2 2026 reduction was Twist Bioscience, cutting an estimated $73M.
  • Soleus Capital Management fully exited Vaxcyte in Q2 2026, selling an estimated $22.4M.
  • Soleus Capital Management's ten largest holdings make up 49% of its $2.9B portfolio in Q2 2026.
  • Soleus Capital Management opened 21 new positions and closed 17 in Q2 2026.
  • Soleus Capital Management's portfolio value rose 18% quarter-over-quarter to $2.9B.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.